BioXcel Therapeutics, Inc. (BTAIQ) Earnings
BioXcel Therapeutics, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
May 15, 2026
From the latest earnings 8-K
Revenue • FY2025
$642K
▼ 71.7%YoY
Diluted EPS • FY2025
-$5.73
▲ 75.6%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from BTAIQ's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $642K | -$69.9M | $478K | -$5.73 | -$57.62M | -7860.0% | -71.7% |
| FY2024 | $2.27M | -$59.6M | $123K | -$23.51 | — | -2967.6% | +64.2% |
| FY2023 | $1.38M | -$179.05M | $120K | -$6.15 | -$155.03M | -12448.0% | +268.0% |
| FY2022 | $375K | -$165.76M | $355K | -$5.92 | -$135.48M | -42572.0% | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| May 15, 2026 | 8-K (2.02) | 0001104659-26-061773EDGAR |
| Mar 27, 2026 | 8-K (2.02) | 0001104659-26-035661EDGAR |
| Nov 12, 2025 | 8-K (2.02) | 0001104659-25-109732EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0001104659-25-076501EDGAR |
| May 12, 2025 | 8-K (2.02) | 0001104659-25-047013EDGAR |
| Mar 27, 2025 | 8-K (2.02) | 0001104659-25-028776EDGAR |
Never miss a BTAIQ filing.
Get an email when BTAIQ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 5, 2026Source: SEC EDGAR.